Premium
Distribution and significance of 14‐3‐3σ, a novel myoepithelial marker, in normal, benign, and malignant breast tissue
Author(s) -
Simpson Peter T,
Gale Theodora,
ReisFilho Jorge S,
Jones Chris,
Parry Suzanne,
Steele Dawn,
Cossu Antonio,
Budroni Mario,
Palmieri Giuseppe,
Lakhani Sunil R
Publication year - 2004
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.1530
Subject(s) - myoepithelial cell , immunohistochemistry , pathology , stromal cell , breast cancer , biology , tissue microarray , invasive lobular carcinoma , carcinoma , cancer , medicine , invasive ductal carcinoma , genetics
14‐3‐3σ is a candidate tumour suppressor gene transactivated by p53 in response to DNA damage. In gene expression analysis of normal luminal and myoepithelial cells, 14‐3‐3σ was preferentially expressed by myoepithelial cells. This study has analysed the immunohistochemical distribution and subcellular localization of 14‐3‐3σ in normal breast tissue and in a large series of benign and malignant breast lesions on whole tissue sections and by tissue microarray. Immunohistochemistry demonstrated that 14‐3‐3σ was consistently expressed in the cytoplasmic compartment and occasionally in the nuclei of myoepithelial cells arranged as a continuous layer around normal ducts and lobular units, whereas luminal epithelial, stromal, endothelial, pericytic, lipomatous, and neural cells showed no staining. Myoepithelial cells of benign proliferations and pre‐invasive lesions were consistently positive for 14‐3‐3σ. Strong expression of 14‐3‐3σ was evident in one case of ductal carcinoma in situ (5.5%) and in 105/554 invasive cancers (18.9%). Survival data were available for 452 patients with invasive breast carcinoma. 14‐3‐3σ cytoplasmic subcellular localization was a statistically significant prognostic factor for the whole series of invasive carcinomas, as well as for those positive for oestrogen (ER) or progesterone receptors (PR). This analysis demonstrates the utility of 14‐3‐3σ as a new adjunct antibody for characterization of myoepithelial cells and myoepithelial lesions and it may be a novel prognostic factor for breast cancer patients. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.